US2002005205A1PendingUtilityA1

Joint repair using mesenchymal stem cells

46
Priority: Apr 25, 2000Filed: Apr 24, 2001Published: Jan 17, 2002
Est. expiryApr 25, 2020(expired)· nominal 20-yr term from priority
Inventors:Francis P. BarryJ. Mary MurphyRobert J. DeansDavid J. FinkAnnemarie Moseley
A61P 25/00A61P 29/00A61K 35/28A61K 2035/124A61P 19/04A61K 35/12A61K 9/0019A61F 2/30756A61F 2/3872C12N 5/0663A61F 2/02A61P 19/02C12N 2510/00
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of repairing a joint in an animal, comprising: injecting into said joint mesenchymal stem cells in conjunction with an acceptable pharmaceutical carrier.  
     
     
         2 . The method of  claim 1  wherein said pharmaceutical carrier is hyaluronan.  
     
     
         3 . The method of  claim 1  wherein said joint is selected from the group consisting of knee, hip, shoulder, ankle, wrist, elbow, tarsal and metatarsal joints, spine and carpal and metacarpal joints.  
     
     
         4 . The method of  claim 1  wherein said mesenchymal stem cells are autologous to the recipient.  
     
     
         5 . The method of  claim 1  wherein said mesenchymal stem cells are allogeneic to the recipient.  
     
     
         6 . A method of treating osteoarthritis in an animal, comprising: 
 injecting into a joint mesenchymal stem cells in conjunction with an acceptable pharmaceutical carrier.    
     
     
         7 . The method of  claim 6  wherein said carrier is hyaluronan.  
     
     
         8 . The method of  claim 6  wherein said joint is selected from the group consisting of knee, hip, shoulder, ankle, wrist, elbow, tarsal and metatarsal joints, spine, carpal and metacarpal joints, and the temporal mandibular joint.  
     
     
         9 . The method of  claim 6  wherein said mesenchymal stem cells are autologous to the recipient.  
     
     
         10 . The method of  claim 6  wherein said mesenchymal stem cells are allogeneic to the recipient.  
     
     
         11 . A method of reducing inflammation in a joint in an animal, comprising: 
 injecting into said joint mesenchymal stem cells in conjunction with an acceptable pharmaceutical carrier.    
     
     
         12 . The method of  claim 11  wherein said acceptable pharmaceutical carrier is hyaluronan.  
     
     
         13 . The method of  claim 11  wherein said joint is selected from the group consisting of knee, hip, shoulder, ankle, wrist, elbow, tarsal and metatarsal joints, spine, carpal and metacarpal joints, and the temporal mandibular joint.  
     
     
         14 . The method of  claim 11  wherein said mesenchymal stem cells are autologous to the recipient.  
     
     
         15 . The method of  claim 11  wherein said mesenchymal stem cells are allogeneic to the recipient.  
     
     
         16 . A method of regenerating meniscal tissue in a joint in an animal, comprising: 
 injecting into said joint mesenchymal stem cells in conjunction with an acceptable pharmaceutical carrier.    
     
     
         17 . The method of  claim 16  wherein said injection is into the joint space of said joint.  
     
     
         18 . The method of  claim 16  wherein said pharmaceutical carrier is hyaluronan.  
     
     
         19 . The method of  claim 16  wherein said joint is selected from the group consisting of knee, hip, shoulder, ankle, wrist, elbow, tarsal and metatarsal joints, and carpal, metacarpal joints, and the temporal mandibular joint.  
     
     
         20 . The method of  claim 16  wherein said mesenchymal stem cells are autologous to the recipient.  
     
     
         21 . The method of  claim 16  wherein said mesenchymal stem cells are allogeneic to the recipient.  
     
     
         22 . A method of stabilizing an injured joint in an animal, comprising: 
 injecting into said joint mesenchymal stem cells in conjunction with an acceptable pharmaceutical carrier.    
     
     
         23 . A method of protecting cartilage in a joint in an animal, comprising: 
 injecting mesenchymal stem cells into said joint in conjunction with an acceptable pharmaceutical carrier.    
     
     
         24 . A method of reducing joint pain in an animal, comprising: 
 injecting mesenchymal stem cells to said joint in conjunction with an acceptable pharmaceutical carrier, whereby said mesenchymal stem cells differentiate into meniscal tissue.    
     
     
         25 . A method of preventing or reducing subchondral bone sclerosis in a joint, comprising: 
 injecting mesenchymal stem cells into said joint in conjunction with an acceptable pharmaceutical carrier.    
     
     
         26 . A method of preventing or reducing the formation of osteophytes in a joint, comprising: 
 injecting mesenchymal stem cells into said joint in conjunction with an acceptable pharmaceutical carrier.    
     
     
         27 . A method of repairing meniscal damage in a joint, comprising: 
 injecting into said joint mesenchymal stem cells in conjunction with an acceptable pharmaceutical carrier, said mesenchymal stem cells being injected in an amount effective to repair said meniscal damage in said joint.

Join the waitlist — get patent alerts

Track US2002005205A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.